Age >80 OR ECOG ≥3 with comorbidity AND asymptomatic NMZL (no GELF criteria) — observatio...
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
| ID | RF-NMZL-FRAILTY-AGE |
|---|---|
| Type | Red flag |
| Status | reviewed 2026-04-25 | pending_clinical_signoff |
| Diseases | DIS-NODAL-MZL |
| Sources | SRC-ESMO-MZL-2024 SRC-NCCN-BCELL-2025 |
Red Flag Origin
| Definition | Age >80 OR ECOG ≥3 with comorbidity AND asymptomatic NMZL (no GELF criteria) — observation appropriate; rituximab monotherapy if treatment indicated. |
|---|---|
| Clinical direction | de-escalate |
| Category | frailty-age |
Trigger Logic
{
"all_of": [
{
"finding": "nmzl_asymptomatic",
"value": true
},
{
"any_of": [
{
"comparator": ">",
"finding": "age_years",
"threshold": 80
},
{
"all_of": [
{
"comparator": ">=",
"finding": "ecog_status",
"threshold": 3
},
{
"comparator": ">=",
"finding": "comorbidity_count",
"threshold": 2
}
]
}
]
}
],
"type": "composite_clinical"
}
Notes
NMZL is indolent like FL; watch-and-wait standard for asymptomatic. Active treatment reserved for symptomatic burden.
Used By
Algorithms
ALGO-NMZL-2L- ALGO-NMZL-2L